Aspirin and ibuprofen enhance pyrazinamide treatment of murine tuberculosis

Journal of Antimicrobial Chemotherapy

Volumn 59, Issue 2, 2007, Pages 313-316

  Byrne, Sean T ^a   Denkin, Steven M ^a   Zhang, Ying ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Chemotherapy; Mycobacterium; NSAIDs; Salicylate; Tuberculosis

Indexed keywords

ACETYLSALICYLIC ACID; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; PYRAZINAMIDE; TUBERCULOSTATIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM DETECTION; COLONY FORMING UNIT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; EXTRAPULMONARY TUBERCULOSIS; FEMALE; LONG TERM CARE; LOW DRUG DOSE; LUNG TUBERCULOSIS; MONOTHERAPY; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OUTCOME ASSESSMENT; RECOMMENDED DRUG DOSE; SPLEEN DISEASE; ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; MICROBIOLOGY; TUBERCULOSIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTITUBERCULAR AGENTS; ASPIRIN; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; FEMALE; IBUPROFEN; MICE; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; TUBERCULOSIS;

EID: 33947535813     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl486     Document Type: Article

References (10)

1. Zhang Y, Mitchison D. The curious characteristics of pyrazinamide: A review. Int J Tuberc Lung Disease 2003; 7: 6-21.
2. Amann R, Peskar BA. Anti-inflammatory effect of aspirin and sodium salicylate. Eur J Pharmacol 2002; 447: 1-9.
3. Ohdo S, Ogawa N, Song JG. Chronopharmacological study of acetylsalicylic acid in mice. Eur J Pharmacol 1995; 293: 151-7.
4. Denkin S, Byrne S, Jie C et al. Gene expression profiling analysis of Mycobacterium tuberculosis genes in response to salicylate. Arch Microbiol 2005; 184: 152-7.
5. Schaller A, Sun Z, Yang Y et al. Salicylate reduces susceptibility of Mycobacterium tuberculosis to multiple antituberculosis drugs. Antimicrob Agents Chemother 2002; 46: 2636-9.
6. Wade MM, Zhang Y. Effects of weak acids, UV and proton motive force inhibitors on pyrazinamide activity against Mycobacterium tuberculosis in vitro. J Antimicrob Chemother 2006; 58: 936-41.
7. Zhang Y, Wade MM, Scorpio A et al. Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J Antimicrob Chemother 2003; 52 790-5.
8. Tyagi S, Nuermberger E, Yoshimatsu T et al. Bactericidal activity of the nitroimmidazopyran PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother 2005; 49: 2289-93.
9. McCune R, McDermott W, Tompsett R. The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. J Exp Med 1956; 104: 763-802.
10. Byrne ST, Denkin SM, Zhang Y. Aspirin antagonism in isoniazid treatment of tuberculosis in mice. Antimicrob Agents Chemother, in press.